Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

    J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

  • Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

    (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell NXTBcpl4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWHRVGVHUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;Mj64PYUuODVizszN MnjRV2FPT0WU
human AN3-CA cell MnjBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{f6U2lvcGmkaYTpc44hd2ZiaIXtZY4hSU5|LVPBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAvODVibl2= NXXMdIhXW0GQR1XS
human CGTH-W-1 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojhTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQxNjBzIH7N NX3jSHRvW0GQR1XS
human GDM-1 cell NU\u[VNXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYK1PHVzUW6qaXLpeIlwdiCxZjDoeY1idiCJRF2tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOy57OTDuUS=> NVvG[VRxW0GQR1XS
human A204 cell NXLL[mtmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2DTN2lvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwPU4xPiCwTR?= NGTOT2NUSU6JRWK=
human G-402 cell M2fpUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\LTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWzNU45PCCwTR?= NVXWfJNHW0GQR1XS
human MFE-296 cell NVjmSFl1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVHSU|diUW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlk3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53OUCyNkDPxE1? MWjTRW5ITVJ?
human NOS-1 cell MlT0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV[1WmpsUW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCrY{WwQVAvPjV7OEeg{txO MoSzV2FPT0WU
human KG-1 cell NXO1Olg4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3LxTGlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|E4PTVizszN M3PI[HNCVkeHUh?=
human HT55 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{HEZ2lvcGmkaYTpc44hd2ZiaIXtZY4hUFR3NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg4QDFizszN MkT6V2FPT0WU
human MG-63 cell MkD5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGryemFKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4xODF2NjFOwG0> MVvTRW5ITVJ?
human CCF-STTG1 cell NIf1UWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnT0TY5pcWKrdHnvckBw\iCqdX3hckBES0ZvU2TUS|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR|UxRTFwMES5PFEh|ryP NYj0ZWE3W0GQR1XS
human RT-112 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXHmVpRyUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFyM{e2JO69VQ>? MXPTRW5ITVJ?
human MC-IXC cell Mn:yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXLSUZlRUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFzNUGyJO69VQ>? Ml:yV2FPT0WU
human HUTU-80 cell NHXlO4ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3q1[2lvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjhzMEOg{txO NUS3[XZkW0GQR1XS
human MV-4-11 cell NEjJ[nNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3T2PGlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzR3MEGg{txO M4LYO3NCVkeHUh?=
human LCLC-103H cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIPtSJVKdmirYnn0bY9vKG:oIHj1cYFvKEyFTFOtNVA{UCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7 MXjTRW5ITVJ?
human G-401 cell M33tNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60OlQzOSEQvF2= NI\X[2hUSU6JRWK=
human A704 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1zQSmlvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlA{OjNizszN Mm\ZV2FPT0WU
human ESS-1 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NY\xOFhHUW6qaXLpeIlwdiCxZjDoeY1idiCHU2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjB|OU[g{txO MWXTRW5ITVJ?
human HLE cell NVvi[oViT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXjUUG5RUW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY{QDB2IN88US=> MXHTRW5ITVJ?
human NY cell M3fuN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoHnTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwOES4NlEh|ryP M1\ac3NCVkeHUh?=
human A427 cell NGjnN|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3TxS2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVgxPzVizszN NXewRVE2W0GQR1XS
human SK-N-DZ cell M3HFR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzOzhzIN88US=> NInYO2tUSU6JRWK=
human J82 cell NEfDe5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHv5[5hKdmirYnn0bY9vKG:oIHj1cYFvKEp6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFYxQDhizszN NVm0RnM2W0GQR1XS
human GI-1 cell NHfseZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlHiTY5pcWKrdHnvckBw\iCqdX3hckBIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yNlk2OSEQvF2= MojjV2FPT0WU
human NCI-H716 cell MoXkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGS3Ro5KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|E3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5|MU[zN{DPxE1? Mlq2V2FPT0WU
human SF126 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUL4cYMzUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDd2NUmg{txO MWLTRW5ITVJ?
human H4 cell NWjPbXg6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53MUK2NkDPxE1? NGTobWlUSU6JRWK=
human LB831-BLC cell M3\KWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEOzWWtKdmirYnn0bY9vKG:oIHj1cYFvKEyEOEOxMWJNSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUS1OlYh|ryP MnW2V2FPT0WU
human HCC1395 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnxNppPUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53OEG1OkDPxE1? M13CVXNCVkeHUh?=
human LK-2 cell M4npbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mlz0TY5pcWKrdHnvckBw\iCqdX3hckBNUy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj62OFU3QSEQvF2= M{XkRXNCVkeHUh?=
human G-361 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmPzTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFQxQDJizszN M1nJUnNCVkeHUh?=
human NCI-H2342 cell NInMNJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2DxVWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwIFnDOVA:Oy5zM{OxOkDPxE1? NYXleJY5W0GQR1XS
human SK-LU-1 cell  M3f1dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoDmTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yQDd4NzFOwG0> MorzV2FPT0WU
human IGROV-1 cell  NXHFPHNpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVHJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI1PzF|IN88US=> NEjPZWdUSU6JRWK=
human EB2 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV6xOIVzUW6qaXLpeIlwdiCxZjDoeY1idiCHQkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI5OTZ6IN88US=> M1HkR3NCVkeHUh?=
human CAL-54 cell MoTHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlg{PjdizszN MVHTRW5ITVJ?
human LB1047-RCC cell MnvNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJG9EXUJvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuN|MyOzZ6IN88US=> M{nzUHNCVkeHUh?=
Daudi cell M2PyRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mon1TY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy53M{G2OEDPxE1? Ml[4V2FPT0WU
human Daudi cell NX7NR5ltT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKGi3bXHuJGRifWSrIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62OlIyQSEQvF2= M3W5eHNCVkeHUh?=
human A172 cell MkfRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFTmTmVKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc{PzlizszN MmfjV2FPT0WU
human KGN cell NX;0d3pOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlfITY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkC2O|A6KM7:TR?= M1fETXNCVkeHUh?=
human SNG-M cell M{HzXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NInrNnZKdmirYnn0bY9vKG:oIHj1cYFvKFOQRz3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDZ4OTFOwG0> NUPRcIdKW0GQR1XS
human SW1710 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFc{OThizszN NFn4fZZUSU6JRWK=
human HT29 cells MX;Qdo9tcW[ncnH0bY9vKGG|c3H5 NYnv[2QySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHzzJIlvKHOncoXtJINwdnSjaX7pcochdWWmaYXt M1PtUVE5PjJyM{iy
human A375P cells NEDrWZpRem:uaX\ldoF1cW:wIHHzd4F6 MnfyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1VEBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= NH;PSW4yQDZ{MEO4Ni=>
human HN5 cells MnOwVJJwdGmoZYLheIlwdiCjc4PhfS=> NFvxTphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= M1\5UVE5PjJyM{iy
HUVEC M3TO[WZ2dmO2aX;uJIF{e2G7 NWHYPGc6OSEQvF2= NUHUbFVNPiCq MUfBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;uJIF1KDBwMTD1UUBi\nSncjC2JIhzeyCkeTDNZZRzcWenbDDhd5NigQ>? M4HoZlI1ODN4MESy
human Daoy cell MorJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWfNeI1IUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44Pzl2OTFOwG0> NV2wOo1IW0GQR1XS
human DMS-273 cell NHi1Tm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2LsemlvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUK3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTZ{MEKg{txO NUHLXllpW0GQR1XS
human KU812 cell M{nNOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFzTZlNKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PzhzMjFOwG0> NVfpWHdGW0GQR1XS
human NCI-H727 cell NITJVlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUTNNo54UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFczPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNEC5NFEh|ryP NX7nXG1mW0GQR1XS
human P30-OHK cell MkDlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2jJTWlvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDZ7NDFOwG0> MXrTRW5ITVJ?
human MIA-PaCa-2 cell M1SyT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJG1KSS2SYVPhMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZyNE[2JO69VQ>? NHTWU2dUSU6JRWK=
human TT cell NXf0WIV{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1;ve2lvcGmkaYTpc44hd2ZiaIXtZY4hXFRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[2NlQh|ryP MULTRW5ITVJ?
human DK-MG cell NYDMcWVTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH;SfmNKdmirYnn0bY9vKG:oIHj1cYFvKESNLV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OjB{ODFOoI0> NIL5dVhUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID